- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06266286
EXOPULSE Mollii Suit & Cerebral Palsy (EXOCEP)
The Effects of EXOPULSE Mollii Suit on Motor Functions in Children With Cerebral Palsy (EXOCEP): A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This work will assess the effects of the EXOPULSE Mollii suit, which is an assistance device applying non-invasive transcutaneous electrostimulation. The EXOPULSE Mollii control unit is a class IIa device, CE marked, and therefore compliant with the Medical Device Directive. Its intended use includes relaxing spastic muscles, maintaining or increasing the range of movement, activating and re-educating muscles, delaying or preventing atrophy due to disuse, increasing local blood flow, and symptomatic relief and management of chronic refractory pain.
The available interventions targeting spasticity are faced with some limitations. For instance, botulinum toxin injection does not seem to improve arm and hand capacity, walking, or quality of life. The available oral agents are challenged by their potential side effects, such as sedation, drowsiness, mental confusion, fatigue, ataxia, hallucination, insomnia, nausea, dry mouth, bradycardia, hypotension, and depression, to cite a few. Therefore, developing novel therapies would help to overcome the actual limitations. Transcutaneous Electrical Nerve Stimulation (TENS) has proven some efficacy in spasticity management. However, one should note that practical difficulties could arise when using TENS at home or in clinical practice (i.e., correctly attaching electrodes). To overcome these limitations, the EXOPULSE Mollii suit has been developed by Exoneural Network, a Swedish med-tech company. It represents an innovative approach for non-invasive electro-stimulation to reduce spasticity and improve motor function.
EXOPULSE Mollii suits consist of body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires, and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery-powered electrical device that sends low-intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
EXOPULSE Mollii suit consists of transcutaneously stimulating the spastic antagonist muscles with an electric current (i.e., low frequency ~20 Hz, low intensity~2 mA), aiming to reduce muscle stiffness. This treatment method's theoretical background primarily refers to the concept of reciprocal inhibition, i.e., that sensory input from a muscle may inhibit the activation of an antagonistic muscle. Thus, the application of the EXOPULSE Mollii suit aims to stimulate a muscle, e.g., the anterior tibialis muscle to reduce reflex-mediated over-activity (i.e., spasticity) of calf muscles by inducing reciprocal inhibition.
There is growing evidence now from pilot applications of EXOPULSE Mollii suit indicating beneficial effects of using this suit on activity (i.e., mobility and gross motor function) and participation.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Samar S AYACHE, MD, PhD
- Phone Number: 0149814662
- Email: samarayache@gmail.com
Study Contact Backup
- Name: Moussa A CHALAH, MD, PhD
- Email: moussachalah@gmail.com
Study Locations
-
-
-
Aix-en-Provence, France
- Recruiting
- Centre Hospitalier Intercommunal D'Aix Pertuis
-
Principal Investigator:
- PASCAL GRANIER, MD
-
Sub-Investigator:
- HELENE RAUSCENT, MD
-
Lyon, France
- Not yet recruiting
- Centre Medico Chirurgical de Readaptation Des Massues
-
Principal Investigator:
- EMMANUELLE CHALEAT - VALAYER, MD
-
Sub-Investigator:
- Marie-Charlotte D'ANJOU, MD
-
Nice, France
- Recruiting
- Centre de Sante Rossetti
-
Principal Investigator:
- GAUTIER DE CHELLE, MD
-
Saint-Trojan-les-Bains, France
- Recruiting
- Centre de Readaptation Pediatrique D'Oleron
-
Principal Investigator:
- SOLENE VIOT, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 5 and 12 years.
- Having a clinical diagnosis of unilateral or bilateral spastic cerebral palsy since at least one month.
- Being able to walk freely, with slight limitation or using ancillary equipment's (Gross Motor Function Classification System (GMFCS) score ≤3).
- Having a PBS score < 45.
- Being French speaker, able to understand verbal instructions, and affiliated to the national health insurance (sécurité sociale).
- Having spasticity with a score of at least 1+ on the MAS
Exclusion Criteria:
- Being included in another research protocol during the study period
- Being unable to undergo medical monitor for the study purposes due to geographical or social reasons
- Having contraindications to wearing EXOPULSE Mollii suit (i.e., implanted electronic medical devices or equipments which can be disrupted by magnets including ventriculoperitoneal shunts and intrathecal baclofen pumps, electronic life support equipment or high-frequency operation equipment, as well as well electrocardiography equipment or cardiac stimulator)
- Having a change in the pharmacological therapy over the last three months
- Suffering from other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain, skin diseases).
- Suffering from a cutaneous disease
- Using another medical device
- Being part of other protected populations as defined in articles L. 1121-5, L. 1121 6,1121-8 and L. 1122-1-2 of the Public Health Code
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Comparator
Active stimulation sessions will last 1 hour each. Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate several groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body. |
Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more |
Sham Comparator: Sham Comparator
In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
|
In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in balance using the PBS (Pédiatric Balance Scale) before and after active and sham stimulation
Time Frame: This will be assessed at baseline (day 1), 2 weeks, 4 weeks, 6 weeks and 8 weeks
|
Balance will be assessed using the 14-item PBS which has well psychometric properties in pediatric patients with cerebral palsy.
The scale rates the balance using 56 points, with higher scores indicating better balance abilities.
|
This will be assessed at baseline (day 1), 2 weeks, 4 weeks, 6 weeks and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the cumulative effects of EXOPULSE Mollii suit on balance using the PBS
Time Frame: This will be assessed at 8 weeks, at 12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
Balance will be assessed using the 14-item PBS which has well psychometric properties in pediatric patients with cerebral palsy.
The scale rates the balance using 56 points, with higher scores indicating better balance abilities.
|
This will be assessed at 8 weeks, at 12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
Evaluation of the effects of EXOPULSE Mollii suit on spasticity using the Modified Ashworth Scale (MAS)
Time Frame: This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
It will be evaluated by examiners using the Modified Ashworth Scale (MAS; scores ranging from 0 to 4 which respectively corresponds to normal muscle tone and rigidity, which has been frequently used in clinical settings to rate muscular tone
|
This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
Evaluation of the effects of EXOPULSE Mollii suit on mobility using the Timed Up and Go test (TUG)
Time Frame: This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
The score is expressed as the time (in seconds) required to perform sequential motor tasks (standing up from the chair, walking to the line on the floor at a normal pace, turning, walking back to the chair at a normal pace and finally sitting down).
|
This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
Quality of life will be measured using the EuroQol 5 dimensions quality of life questionnaire for youth (EQ-5D-Y)
Time Frame: This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
This variable will be measured using the EuroQol 5 dimensions quality of life questionnaire for youth (EQ-5D-Y), a scale developed by EuroQoL group for the pediatric population and has good psychometric properties in children and adolescent.
EQ-5D-Y evaluates five dimensions: anxiety/depression, mobility, pain/difficulty, selfcare, and usual activities.
The score of each dimension is calculated by assigning a numerical value to each response level (i.e., 1 for "no problems", 5 for "extreme problems"/"unable to") and summing these values across the five items, resulting in a score raning from 5 (no problems on any dimension) to 25 (extreme problems on all dimensions).
|
This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
Pain will be assessed using the Pain Scale Chart (PSC)
Time Frame: This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks,12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
Patients suffering from pain are asked to fill in the Pain Scale Chart (PSC) scored from 0 to 10 for pain.
0 meaning no pain and 10 meaning the worst pain experienced.
|
This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks,12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
Evaluation of overall improvement using the Clinical Global Impression (CGI)
Time Frame: This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks,12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
It's consisting of 7-point scale ranging from "very much improved since the initiation of treatment" to "very much worse since the initiation of treatment" (from 1 to 7)
|
This will be assessed at Day 1, 2 weeks, 4 weeks, 6 weeks, 8 weeks,12 weeks, and at 32 weeks of using EXOPULSE Mollii suit
|
Collaborators and Investigators
Investigators
- Study Director: Samar S AYACHE, MD, PhD, Clinical Neurophysiology department, Henri Mondor Hospital, Creteil, France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-A00233-40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Palsy
-
Gazi UniversityCompletedCerebral Palsy | Cerebral Palsy, Spastic | Cerebral Palsy Spastic Diplegia | Cerebral Palsy Quadriplegic | Cerebral Palsy, MonoplegicTurkey
-
Northwestern UniversityActive, not recruitingCerebral Palsy | Diplegic Cerebral Palsy | Bilateral Cerebral PalsyUnited States
-
Centre Médico-Chirurgical de Réadaptation des Massues...RecruitingCerebral Palsy, Dyskinetic | Cerebral Palsy, Spastic | Infantile Hemiplegic Cerebral PalsyFrance
-
St Mary's University CollegeUniversity of GloucestershireUnknownCerebral Palsy | Cerebral Palsy Ataxic | Cerebral Palsy, MixedUnited Kingdom
-
Hilde FeysHasselt University; ETH Zurich; Curtin UniversityRecruitingHemiplegic Cerebral Palsy | Cerebral Palsy, SpasticBelgium
-
University of California, San FranciscoNational Institutes of Health (NIH)RecruitingDystonic Cerebral Palsy | Dyskinetic Cerebral PalsyUnited States
-
MTI UniversityEnrolling by invitationSpastic Diplegic Cerebral PalsyEgypt
-
East Carolina UniversityRecruitingHemiplegic Cerebral Palsy | Unilateral Cerebral Palsy | Remote Ischemic ConditioningUnited States
-
October 6 UniversityCompletedSpastic Cerebral Palsy | Spastic Hemiplegic Cerebral PalsyEgypt
-
Marmara UniversityUnknownCerebral Palsy, Spastic | Cerebral Palsy, Spastic, DiplegicTurkey
Clinical Trials on EXOPULSE MOLLII SUIT (active)
-
Exoneural Network ABHannover Medical School; Ottobock SE & Co. KGaA; Pohlig GmbHRecruitingCerebral Palsy | Hemiplegia | Tetraplegia | Pain Syndrome | Spasticity | Balance | Muscle | DiplegiaGermany
-
Institut De La Colonne Vertebrale Et Des NeurosciencesCompleted
-
Danderyd HospitalRecruitingStroke | Pain, Shoulder | Technology | TherapeuticsSweden
-
Exoneural Network ABNot yet recruitingStroke | Multiple Sclerosis | Cerebral Palsy | Spinal Cord Injuries | Neurologic DisorderSweden
-
Sheikh Shakhbout Medical CityRecruitingNervous System Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | FibromyalgiaUnited Arab Emirates
-
Sheikh Shakhbout Medical CityRecruitingStroke | Spasticity, Muscle | SpasticUnited Arab Emirates
-
Institut De La Colonne Vertebrale Et Des NeurosciencesRecruiting
-
Kastamonu UniversityGazi UniversityRecruitingCerebral Palsy | Spasticity, MuscleTurkey
-
Kırıkkale UniversityGazi UniversityRecruitingCerebral Palsy | Mollii SuitTurkey
-
Sheikh Shakhbout Medical CityRecruitingSpasticity, Muscle | Oxygen Consumption | Sclerosis, Multiple | Spastic | MS (Multiple Sclerosis)United Arab Emirates